Last reviewed · How we verify
NCT03633162: MGBIG
Maternal Grandmothers in the Born in Guangzhou Cohort Study
trial in Hereditary Transmission in 5,000 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Guangzhou Women and Children's Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 21 May 2018 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2038 |
| Sites | 1 location across China |
Conditions studied
- Hereditary Transmission — all drugs for Hereditary Transmission →
- Immune Development — all drugs for Immune Development →
- Childhood Obesity — all drugs for Childhood Obesity →
- Host and Microbiome — all drugs for Host and Microbiome →
Sponsor
Guangzhou Women and Children's Medical Center
Who can join
Adults 36 to 100, female only, with Hereditary Transmission or Immune Development. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The MGBIG is a study exploring cross-generational effects in 5000 women and their children and grandchildren located in Guangzhou, China. Its initial aim is to facilitate research on understanding the interplay between genes and environmental factors on disease etiology and on explaining the cause of the disease from the perspective of "grandmother-mother-child" heredity. Data are collected regarding environmental exposures, lifestyle, and social support on grandmother from birth to old age. Biological samples including blood and tissue samples are collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03633162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Guangzhou Women and Children's Medical Center trials
Trials by the same sponsor.
- NCT07190001 — YOLT-204 in Patients With Hemoglobinopathies · EARLY_PHASE1 · not yet recruiting
- NCT06904729 — Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children · Phase 3 · recruiting
- NCT06948994 — A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Di · Phase 1, PHASE2 · not yet recruiting
- NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
- NCT06731205 — Long-term Renal Prognosis of Neonatal Acute Kidney Injury · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03633162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Women and Children's Medical Center
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03633162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing